Cargando…
Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children
Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866445/ https://www.ncbi.nlm.nih.gov/pubmed/36680134 http://dx.doi.org/10.3390/v15010094 |
_version_ | 1784876093349560320 |
---|---|
author | Reiff, Daniel D. Cron, Randy Q. |
author_facet | Reiff, Daniel D. Cron, Randy Q. |
author_sort | Reiff, Daniel D. |
collection | PubMed |
description | Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage. Adequate timely treatment can prevent poor outcomes in the short term, but long-term data is lacking. Methods: A large single center MIS-C cohort was followed longitudinally after treatment with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine the natural history of the disease and to describe improvement in laboratory markers and cardiac outcomes. Patient were stratified by disease severity and compared. Results: 137 patients were identified with demographics similar to previously described cohorts. Regardless of disease severity, when adequately treated, initial lab abnormalities rapidly improved by the 6–8 month follow-up period, with some resolved in as little as 1–2 weeks. Similarly, cardiac abnormalities improved quickly after treatment; all abnormalities resolved in this cohort by 1–2 months post-hospitalization. Conclusions: Although MIS-C is a serious sequela of COVID-19, when identified quickly and treated aggressively, laboratory abnormalities, coronary dilatation, and systolic dysfunction rapidly improve with minimal long-term morbidity or mortality. |
format | Online Article Text |
id | pubmed-9866445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98664452023-01-22 Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children Reiff, Daniel D. Cron, Randy Q. Viruses Article Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) in the pediatric population. The disease is manifested by hyperinflammation and can result in cardiac dysfunction, coronary changes, and end-organ damage. Adequate timely treatment can prevent poor outcomes in the short term, but long-term data is lacking. Methods: A large single center MIS-C cohort was followed longitudinally after treatment with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine the natural history of the disease and to describe improvement in laboratory markers and cardiac outcomes. Patient were stratified by disease severity and compared. Results: 137 patients were identified with demographics similar to previously described cohorts. Regardless of disease severity, when adequately treated, initial lab abnormalities rapidly improved by the 6–8 month follow-up period, with some resolved in as little as 1–2 weeks. Similarly, cardiac abnormalities improved quickly after treatment; all abnormalities resolved in this cohort by 1–2 months post-hospitalization. Conclusions: Although MIS-C is a serious sequela of COVID-19, when identified quickly and treated aggressively, laboratory abnormalities, coronary dilatation, and systolic dysfunction rapidly improve with minimal long-term morbidity or mortality. MDPI 2022-12-29 /pmc/articles/PMC9866445/ /pubmed/36680134 http://dx.doi.org/10.3390/v15010094 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Reiff, Daniel D. Cron, Randy Q. Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children |
title | Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children |
title_full | Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children |
title_fullStr | Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children |
title_full_unstemmed | Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children |
title_short | Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children |
title_sort | timely resolution of sars-cov-2-related multi-system inflammatory syndrome in children |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866445/ https://www.ncbi.nlm.nih.gov/pubmed/36680134 http://dx.doi.org/10.3390/v15010094 |
work_keys_str_mv | AT reiffdanield timelyresolutionofsarscov2relatedmultisysteminflammatorysyndromeinchildren AT cronrandyq timelyresolutionofsarscov2relatedmultisysteminflammatorysyndromeinchildren |